Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

imSAVAR

Financiado

Cerrado

Immune Safety Avatar nonclinical mimicking of the immune system effects of immu...

Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapies The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy. Existing nonclinical models do not adequately represent the complexity o... ver más

30/11/2025

Fraunhofer

22M€

Presupuesto del proyecto: 22M€

Líder del proyecto

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 28 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-18

IMI2-2018-15-04: Emerging translational safety techn...

I+D

Cerrada hace 6 años

0% 51% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

28 Participantes

Fraunhofer

3.51M€ | Lider

MOBEL LINEA

536.92K€ | Participante

UNIVERSITATSKLINIKUM JENA

511.17K€ | Participante

BIOS

288.75K€ | Participante

Proyectos interesantes

BIOVACSAFE

Medical Technol...

Data Science

31M€ Cerrado

AISAT

Medical Technol...

Data Science

178K€ Cerrado

ENCITE

Medical Technol...

Data Science

16M€ Cerrado

Biosafety

Medical Technol...

Biotechnology

900K€ Cerrado

PTQ-08-03-07707

Medical Technol...

Data Science

44K€ Cerrado

Anti-IL-6

Medical Technol...

Data Science

4M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 72 meses Fecha Inicio: 2019-11-18
Fecha Fin: 2025-11-30

Líder del proyecto

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 22M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy. Existing nonclinical models do not adequately represent the complexity of the immune system and its interactions in both immunoncology and immunmediated diseases. They also do not accurately reflect the diversity of response to new therapies that is seen in clinical medicine. We will, thus, constantly refine existing and develop new nonclinical models with the final goal of validation aiming at: (i) understanding the value of nonclinical models for predicting efficacy and safety of immunomodulators incorporating cellular high throughput assays, complex organisms models and micro physiological systems, (ii) developing new endpoints and better monitoring approaches for immune function tests, and (iii) designing cellular and molecular biomarkers for early detection of adverse effects. The platform imSAVAR will be based upon case studies for prioritized therapeutic modalities and has been built around institutes of the Fraunhofer-Gesellschaft which has strong track records in applied science and in particular toxicology. The consortium will improve the prediction of the transferability of safety and efficacy of immunomodulators from pre-clinical models to first-in-human studies in collaboration with the private sector, pharma, regulators and technology providers. We will share experience on customized models that can be deployed (w.r.t. the 3Rs principles), establish the necessary infrastructure, conduct the analyses and provide wider disease domain expertise. This conjoint effort assures that the platform imSAVAR constantly benefits the field of immune safety evaluation, and will generate opportunities for European businesses. A guiding principle of this consortium is the meaningful engagement of multiple stakeholders including patients and regulators. A multi-stakeholder community will be established.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores